WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
฿5,20
0,00%
(0,00) 1 HR
15 Okt, 16.40.00 GMT+7 · THB
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk WUXI06...
Pembukaan
฿5,25
Tinggi
฿5,35
Rendah
฿5,05
Kapitalisasi pasar
200,24 M
Volume rata-rata
93,60 rb
Volume
288,50 rb
Harga tinggi dalam 52 minggu terakhir
฿6,25
Harga rendah dalam 52 minggu terakhir
฿3,02
Saham beredar
4,12 M
Jumlah karyawan
15 rb
Pembukaan
฿5,25
Tinggi
฿5,35
Rendah
฿5,05
Kapitalisasi pasar
200,24 M
Volume rata-rata
93,60 rb
Volume
288,50 rb
Harga tinggi dalam 52 minggu terakhir
฿6,25
Harga rendah dalam 52 minggu terakhir
฿3,02
Saham beredar
4,12 M
Jumlah karyawan
15 rb
Artikel berita
Dari sumber web dan partner berita
Pluang
·
1 hari yang lalu
Opsi S&P 500 kuasai volume $640 juta di Hyperca...
BeInCrypto
·
11 jam yang lalu
S&P 500 Masuk ke Periode Musiman Terkuat
Rmol.id
·
11 jam yang lalu
Wall Street Anjlok, Nasdaq Tertekan Inflasi AS
Investing.com Indonesia
·
1 jam yang lalu
S&P 500 Energi naik +46% YTD, strategi saham AI ini melonjak +78%
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tentang Wuxi Biologics (Cayman) Inc. KKPS DR